Somewhere between a hospital discharge order and a nurse at the front door, there is a phone call. That call decides almost everything. It determines whether a patient waits four days for antibiotics or gets treated tomorrow. It determines whether a referral coordinator spends an afternoon chasing a callback. As home infusion grows toward a forty billion dollar market, that phone call is the industry’s most underbuilt infrastructure. This is why home infusion therapy patient support outsourcing is no longer a nice-to-have for infusion pharmacies. The intake desk deserves as much strategic attention as the nursing schedule.
Grand View Research projects the home infusion market will grow at a 7.8% compound annual rate through 2033. That growth reaches close to forty billion dollars, driven by the shift toward lower-cost, more convenient sites of care. That is not a modest trend line. It is a structural rewrite of where American healthcare happens.
Yet Cencora’s Pharmacy Outlook 2026 survey found something almost comedic given those growth numbers. Fully 82% of health systems manage a quarter or fewer of their infusion patients at home. Meanwhile, systems running home infusion programs report an average of twenty million dollars in annual revenue. Somewhere, a CFO stares at that number. Why does the program still run on a fax machine and one overworked coordinator named Denise?
Why Home Infusion Intake Call Center Capacity Is the Real Growth Bottleneck
Every infusion pharmacy leader will admit nursing capacity is tight. Fewer will admit intake is tighter still. A referral arrives, and someone has to verify insurance, confirm the diagnosis code, and check site-of-care restrictions. They also have to schedule the first visit, often within hours, to avoid a readmission. Miss that window, and the patient ends up back in a hospital bed. That bed costs the system far more than home care ever would. A dedicated home infusion intake call center exists precisely to prevent that miss, working alongside strong eligibility verification processes so authorization delays never become the reason care stalls. Most infusion providers still have not built one at scale.
The problem is not that infusion pharmacies lack good staff. The problem is that referral volume is lumpy, unpredictable, and constant. A single hospital system can send twelve referrals on a Monday and two on a Wednesday. Staffing to the Monday peak means paying for idle capacity most of the week. Staffing to the average, however, means every peak turns into a backlog. Backlogs in home infusion are never abstract inefficiencies. They are patients sitting at home without medication.
What Breaks First When Referral Volume Climbs
Intake breaks first, and it breaks quietly. Nobody notices a missed authorization deadline until the pharmacy gets a denial three weeks later. Nobody notices a patient who gave up calling back, at least not until that patient chooses a competitor. Connie Sullivan, President and CEO of the National Home Infusion Association, has been direct about the stakes involved. She has noted that home-based care lets beneficiaries receive treatment in the setting they overwhelmingly prefer: their own homes. Patients clearly want this care. Unfortunately, the industry’s back office often cannot process the demand fast enough to deliver it.
Infusion Therapy Scheduling Support Is the Second Bottleneck Nobody Budgets For
Intake gets the referral through the door. Scheduling then has to align a specialty-trained nurse with a delivery window for supplies. It also has to work around a patient’s actual availability. Many therapies must start within a narrow clinical timeframe, which raises the stakes further. Consequently, infusion therapy scheduling support has become its own specialized discipline, one that draws on the same rigor Ameridial applies to broader medical appointment scheduling work but tunes it to infusion-specific clinical windows. It differs meaningfully from general scheduling. A missed reschedule call for a routine checkup is merely inconvenient. A missed reschedule call for a weekly IVIG infusion can trigger a flare and an ER visit.
This is where the site-of-care shift creates real operational tension. Payers actively push patients toward home infusion because it costs less than a hospital outpatient department. Meanwhile, the supporting infrastructure has not scaled at the same pace as demand. That infrastructure includes intake staff, scheduling coordinators, and reauthorization trackers. Grand View’s own analysis states plainly that infusion therapy is migrating toward lower-acuity, lower-cost environments. That migration keeps accelerating, whether or not the back office is ready.
A Real-Life Example: How Scale Gets Managed at Option Care Health
Option Care Health, the nation’s largest independent home infusion provider, offers a useful reference point. According to its 2025 full-year earnings results, the company served over 315,000 unique patients last year. It also completed more than 2,500,000 infusion events in that same period. On the earnings call, CEO John Rademacher framed the company’s model around putting patients first at national scale. The company also reported that roughly 40% of claims now process without human intervention. That single statistic tells you almost everything about where this industry is headed. Growth at that scale is impossible without automation working alongside trained human teams. It is equally impossible without a back office built to absorb volume spikes instead of drowning in them.
Why Home Infusion Therapy Patient Support Outsourcing Beats Simply Hiring More Staff
Faced with rising volume, the instinctive response is to hire more intake coordinators. That instinct is understandable, and it is also usually wrong. New hires need months of training before they can navigate payer-specific authorization rules with any confidence. They also need time to learn home infusion accreditation requirements. And they need the emotional steadiness to talk with a frightened patient facing a central line at home. Turnover in entry-level healthcare support roles remains stubbornly high across the industry. As a result, training investment frequently walks out the door within a year.
Home infusion therapy patient support outsourcing solves a different problem than headcount solves. A specialized partner brings pre-trained agents who already understand HIPAA-compliant intake workflows. They already understand insurance verification and infusion-specific scheduling constraints too. Just as importantly, outsourced capacity flexes with referral volume instead of sitting idle between peaks. When Monday brings twelve referrals and Wednesday brings two, a scalable team absorbs the swing easily. No hiring cycle or layoff conversation is required. That flexibility is genuinely difficult to replicate with a fixed internal headcount model.
Where Ameridial Draws the Line Differently
There is a differentiation point worth naming directly here. Many healthcare BPOs treat infusion intake as a generic subset of pharmacy call center work. It becomes just another queue in a shared pool of agents. Infusion intake deserves dedicated protocol training instead. A missed step in site-of-care determination can delay treatment for a patient managing cancer or a serious infection. So can a misrouted prior authorization. Ameridial pairs its eligibility verification expertise with its medical appointment scheduling capabilities, an approach detailed further in Ameridial’s healthcare call center outsourcing guide. Intake, authorization, and first-visit scheduling then function as one coordinated workflow, not three disconnected handoffs.
Ask Yourself These Questions Before the Next Referral Surge
Consider a few diagnostic questions before the next referral wave hits your intake desk. How many hours typically pass between referral receipt and first patient contact? What percentage of referrals stall because of incomplete insurance verification? Does your scheduling team have real-time visibility into nursing availability across your service area? If those answers make you uncomfortable, you are not alone. You are also not without options.
Turning Site-of-Care Growth Into Sustainable Patient Access
The home infusion market is not going to slow down. Payers, too, are not going to stop pushing volume toward lower-cost settings. Therefore, the organizations that win will treat intake and scheduling as strategic infrastructure. They will not treat it as administrative overhead. Ameridial supports infusion pharmacies and health systems with care coordination and care transition support built for complex, time-sensitive referrals. That support is backed by revenue cycle management expertise, keeping authorizations and claims moving with patient care, and it sits alongside Ameridial’s broader work with healthcare providers nationwide.
If your intake desk is buckling under referral growth, it may be time for a second set of hands. The same goes if your scheduling team cannot keep pace with the site-of-care shift. Book a consultation with Ameridial’s healthcare team. Together, we can build an intake and scheduling model that scales with your patients, not against them.
